Overview

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

Status:
Active, not recruiting

Trial end date:
2021-12-03

Target enrollment:

Participant gender:

Summary

Interventional, multicenter, open-label, 20 weeks study - To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena. - To identify efficacy and safety in switching from oral atypical antipsychotics other than aripiprazole to Abilify Maintena

Phase:

Phase 4

Details

Lead Sponsor:

Korea Otsuka Pharmaceutical Co., Ltd.

Treatments:

Aripiprazole